Your SlideShare is downloading. ×
0
Carla botting malaria vaccines oct 14 2013
Carla botting malaria vaccines oct 14 2013
Carla botting malaria vaccines oct 14 2013
Carla botting malaria vaccines oct 14 2013
Carla botting malaria vaccines oct 14 2013
Carla botting malaria vaccines oct 14 2013
Carla botting malaria vaccines oct 14 2013
Carla botting malaria vaccines oct 14 2013
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×
Saving this for later? Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime – even offline.
Text the download link to your phone
Standard text messaging rates apply

Carla botting malaria vaccines oct 14 2013

461

Published on

Published in: Health & Medicine
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
461
On Slideshare
0
From Embeds
0
Number of Embeds
4
Actions
Shares
0
Downloads
2
Comments
0
Likes
0
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

Transcript

  • 1. PLANNING FOR ADULT VACCINATION WORKSHOP AERAS - SEPT 4, 5, 2013 Malaria Vaccines Change from control to elimination/ eradication Carla Botting Director Product Development and Access
  • 2. Malaria Disease Burden Malaria epidemiology: • Globally, 3.3 billion at risk of malaria* • ~219 million (154M-289M) cases/year, 79% in sub-Saharan Africa • 90% of these cases are caused by P. falciparum • ~660,000 (490K-896K) deaths/year, 90% in sub-Saharan Africa * WHO World Malaria Report 2012 Pf EIR >100 10 1 0.1 Gething, P.W., et al., A new world malaria map: Plasmodium falciparum endemicity in 2010. Malar J, 2011. 10: p. 378. 2
  • 3. 2006 Malaria vaccine community goal Strategic Goal * : To develop an 80% efficacious malaria vaccine by 2025 that would provide protection for at least four years – Landmark Goal: To develop and license a first-generation malaria vaccine that has protective efficacy of more than 50% against severe disease and death and lasts longer than one year Malaria Vaccine Technology Roadmap http://www.malariavaccineroadmap.net/ *WHO is currently leading the process to revise to the Strategic Goal – the Landmark Goal will not change 3
  • 4. Updated Strategic Goal & Outcomes • A world free of malaria in part due to affordable access to malaria vaccines that prevent disease and death caused by and/or interrupt transmission of P. falciparum and P. vivax in all ages and in all endemic settings. Goal/Impact Outcome Transmission Interrupted Saving Lives & Preventing Disease Control & Elimination Infections Prevented Cases Averted* *Impact on asymptomatic reservoir? 4 4
  • 5. Updated Strategic Goal, Outcomes, & Targets • A world free of malaria in part due to affordable access to malaria vaccines that prevent disease and death caused by and/or interrupt transmission of P. falciparum and P. vivax in all ages and in all endemic settings. Saving Lives & Preventing Disease Goal/Impact Control & Elimination Outcome Transmission Interrupted Infections Prevented Cases Averted* Sexual/ Sporogonic/ Mosquito (SSM) Preerythrocytic (PE) Blood Stage (BS) Vaccine Target 5 5
  • 6. Three priority program areas • A world free of malaria in part due to affordable access to malaria vaccines that prevent disease and death caused by and/or interrupt transmission of P. falciparum and P. vivax in all ages and in all endemic settings. Goal/Impact Outcome Transmission Interrupted Saving Lives & Preventing Disease Control & Elimination Infections Prevented Cases Averted* Vaccine Target 4 priority program areas TBVs ppRTS,S & eeRTS,S Next Gen 6 6
  • 7. RTS,S present and future ppRTS,S Prevention of pediatric malaria RTS,S eeRTS,S Elimination / eradication RTS,S Current TPP for RTS,S, which focuses on prevention of pediatric malaria clinical and severe disease Evaluation of current RTS,S construct to determine whether it could facilitate elimination in some settings  Would require deploying the current construct to the entire population at risk, not just infants / toddlers eeRTS,S+ Next generation elimination / eradication RTS,S Adding components to the current RTS,S construct to make a more highly efficacious malaria vaccine that could contribute to elimination in an entire at risk population 7
  • 8. THANK YOU

×